Response Genetics Partners With NeoGenomics to Offer Cancer Tests
Posted on: Tuesday, 30 September 2008, 09:01 CDT
Response Genetics, a developer of clinical diagnostic tests for cancer, has announced an agreement with NeoGenomics Laboratories, a clinical laboratory service provider of oncology focused genetic diagnostic tests, and the formation of its own sales team, as part of its sales strategy to offer its ResponseDX: Colon and ResponseDX: Lung tests nationwide.
ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to help physicians with therapeutic treatment decisions for patients with non-small cell lung cancer and colorectal cancer.
In addition to Response Genetics offering its ResponseDX tests through its own newly formed specialized sales team, and under the terms of the agreement, NeoGenomics will be the exclusive national clinical reference laboratory authorized to offer Response Genetics's proprietary tests through their own proven national sales force. All tests will be performed through Response Genetics's Clinical Laboratory Improvement Amendment-certified laboratory.
Robert Gasparini, president and chief scientific officer of NeoGenomics, said: "We could not be more pleased than to have Response Genetics as a partner in this endeavor. We believe this combination of two leaders in molecular diagnostics will allow us to establish new accounts, differentiate our services, and increase our footprint in the expanding field of molecular cancer genetics."
Source: Datamonitor
Related Articles
- Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups
- Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics
- Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
- Parents' Initiative Pediatric Cancer Clinic Donation to Be Used for Purchase of a BSD-2000/3D/MR in Germany
- Cancer Clinics of Excellence(TM), New National Network of Oncologists, Launches With Goal of Improving Quality of Cancer Care
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- Newsweek Hosts Special Capitol Hill Panel Discussion on 'The New Age of Cancer Clinical Trials: Issues and Opportunities'
- 17,500 Participants Needed to Enroll in Major Colorectal Cancer Clinical Trials; CancerTrialsHelp.Org Launches QuickLink
- Cancer Clinic Cuts Diagnosis Time
 |
 |
User Comments (0)
RSS Feeds